Therapies targeting anti-angiogenesis or targeting immune check points in tumor environment have been developed to treat various tumors, such as anti-VEGF antibody, bevacizumab, and anti-PD-1 antibody, pembrolizumab. Here, VEGFA is linked to neoplasm.